Dr. Clay Siegall, Ph. D. a George Washington University trained geneticist, author of over 70 publications and owner of 15 patents, previously worked with Bristol-Myers Squibb, the National Institute of Health and the National Cancer Center. He was therefore the ideal candidate to become co-founder, President and CEO of Seattle Genetics, a Biotechnology company founded in 1998 based in Washington.
Now a leading developer of clinical and pre-clinical cancer treatment products, the company first focused on the development of antibody-based therapies, called antibody-drug conjugates (ADCs). In 2011 the U.S. Food and Drug Administration (FDA) granted accelerated approval for its groundbreaking ADC product, ADCETRIS (brentuximab vedotin) which reduces the toxic effects of chemotherapy and increases antitumor activity. It has been used to treat over 15,000 Hodgkin’s lymphoma and acute myeloid leukemia patients in over 65 countries.
The company has partnered with companies such as Genentech, Bayer Pharmaceuticals Corporation, Curagen and Medimmune and has licenses with biotechnology enterprises such as Celldex Therapeutics Inc., GlaxoSmithKline LLC, AbbVie Biotechnology Ltd, Pfizer, Oxford Bio Therapeutics Inc. and Genentech (Roche). Significant achievements were achieved through such collaborative efforts, including the development of anti-body T-cell receptor (ACTR) cancer treatments. The collaboration with Unnum Therapeutics generated $645 Million in the development of anti-body T-cell receptor (ACTR) cancer therapies.
Dr. Clay Siegall is a Board member of companies such as Alder BioPharmaceuticals, a private biotechnology company, the Fred Hutchinson Cancer Research Centre, Ultragenyx, the Washington Biotech BioMedical Association (WBBA) and Mirna Therapeutics Inc.
Mirna is involved in the development of MicroRNA-based therapeutics, a new and exciting area of cancer research. The success of these miRNAs therapies is extremely important since it has been recognized that important embryonic developments such as immunity, cellular growth and proliferation and immunity, depend on the precise functioning of the miRNAs. Since their malfunction seems connected with the development of many cancers, the use of strategies to replace malfunctioning miRNAs is vitally important to the eventual control and eradication of cancer.
Dr. Siegall’s pharmaceutical industry experience and achievements in the field of oncology product development are therefore significant benefits to this work in progress.
Learn more here: